Collaboration In The Pharmaceutical Industry

Collaboration In The Pharmaceutical Industry Book in PDF, ePub and Kindle version is available to download in english. Read online anytime anywhere directly from your device. Click on the download button below to get a free pdf file of Collaboration In The Pharmaceutical Industry book. This book definitely worth reading, it is an incredibly well-written.

Extending the Spectrum of Precompetitive Collaboration in Oncology Research

Author : Institute of Medicine,Board on Health Care Services,National Cancer Policy Forum
Publisher : National Academies Press
Page : 112 pages
File Size : 49,9 Mb
Release : 2010-10-15
Category : Medical
ISBN : 9780309156547

Get Book

Extending the Spectrum of Precompetitive Collaboration in Oncology Research by Institute of Medicine,Board on Health Care Services,National Cancer Policy Forum Pdf

Despite spending more time and money in developing novel therapeutics, the success rate for new pharmacologic treatments has been poor. Although the research and development expenditures have grown 13 percent each year since 1970 (a 50-fold increase), the number of new drugs approved annually is no greater now than it was 50 years ago. Over the past decade, skyrocketing costs and the complexity of the scientific knowledge upon which to develop new agents have provided incentives for alternative approaches to drug development, if we are to continue to improve clinical care and reduce mortality. These challenges create opportunities for improved collaboration between industry, academia, government, and philanthropic organizations at each stage in new drug development, marketing, and implementation. Perhaps the most appropriate initial step in addressing the need for collaboration is to consider more precompetitive relationships that allow sharing of scientific information to foster drug development. While these collaborative relationships in basic and preclinical research on drug targets and the early stages of clinical testing are acknowledged to be potentially important drivers for innovation and more rapid marketing of new agents, they also raise a number of concerns that must be addressed. For example, acknowledgment of academic productivity and independence and economic competitiveness must be considered and these challenges managed to foster a culture of collaboration. At the same time, regulatory issues, the need for standardization, and intellectual property concerns must be confronted if the current models for drug development are to be refined to encourage robust participation in precompetitive collaborations. Recognizing the growing importance of precompetitive collaborations in oncology drug development, as well as the challenges these innovative collaborations pose, the National Cancer Policy Forum of the Institute of Medicine held a workshop on February 9 and 10, 2010. This book is a summary of the workshop proceedings.

Collaborative Innovation in Drug Discovery

Author : Rathnam Chaguturu
Publisher : John Wiley & Sons
Page : 768 pages
File Size : 43,7 Mb
Release : 2014-04-14
Category : Medical
ISBN : 9780470917374

Get Book

Collaborative Innovation in Drug Discovery by Rathnam Chaguturu Pdf

Can academia save the pharmaceutical industry? The pharmaceutical industry is at a crossroads. The urgent need for novel therapies cannot stem the skyrocketing costs and plummeting productivity plaguing R&D, and many key products are facing patent expiration. Dr. Rathnam Chaguturu presents a case for collaboration between the pharmaceutical industry and academia that could reverse the industry's decline. Collaborative Innovation in Drug Discovery: Strategies for Public and Private Partnerships provides insight into the potential synergy of basing R&D in academia while leaving drug companies to turn hits into marketable products. As Founder and CEO of iDDPartners, focused on pharmaceutical innovation, Founding president of the International Chemical Biology Society, and Senior Director-Discovery Sciences, SRI International, Dr. Chaguturu has assembled a panel of experts from around the world to weigh in on issues that affect the two driving forces in medical advancement. Gain global perspectives on the benefits and potential issues surrounding collaborative innovation Discover how industries can come together to prevent another "Pharma Cliff" Learn how nonprofits are becoming the driving force behind innovation Read case studies of specific academia-pharma partnerships for real-life examples of successful collaboration Explore government initiatives that help foster cooperation between industry and academia Dr. Chaguturu’s thirty-five years of experience in academia and industry, managing new lead discovery projects and forging collaborative partnerships with academia, disease foundations, nonprofits, and government agencies lend him an informative perspective into the issues facing pharmaceutical progress. In Collaborative Innovation in Drug Discovery: Strategies for Public and Private Partnerships, he and his expert team provide insight into the various nuances of the debate.

Collaboration in the Pharmaceutical Industry

Author : Viviane Quirke
Publisher : Routledge
Page : 371 pages
File Size : 51,9 Mb
Release : 2012-10-12
Category : History
ISBN : 9781134390984

Get Book

Collaboration in the Pharmaceutical Industry by Viviane Quirke Pdf

Examining the issue of 'British decline' after the war, this fascinating text describes the evolution of cooperation in Britain and France, and argues that the relationship between these two countries helped to disseminate a culture of research, resulting in the transformation of the medical sciences and the pharmaceutical industry in both countries. Of interest to a wide range of academic disciplines, this highly relevant book discusses topics including penicillin, sulphamide drugs, and the effects of war in both countries.

The Core Model

Author : Ibis Sanchez-Serrano
Publisher : Academic Press
Page : 174 pages
File Size : 45,6 Mb
Release : 2019-09-15
Category : Medical
ISBN : 9780128142936

Get Book

The Core Model by Ibis Sanchez-Serrano Pdf

The Core Model: A Collaborative Paradigm for the Pharmaceutical Industry and Global Health Care develops the innovative core model, an organizational research and design paradigm and economic theory that proposes a collaborative approach to resolving global health issues and improving the productivity of drug development. The model proposes that scientific collaboration does not occur in an unstructured manner, but actually takes place within a highly structured order where knowledge is transferred, integrated and finally translated into commercial products. An understanding of this model will help solve the global pharmaceutical industry ́s productivity problems and address important global health care and economic issues. This book is useful to researchers, advanced students, regulators, and management in pharmaceutical industries, as well as healthcare professionals, those working in health economics, and those interested in scientific innovation processes. Explores the current state-of-the-art in the pharmaceutical industry and the global healthcare sector Includes insights from world-leading figures in the pharmaceutical industry, healthcare sector, federal funding agencies, regulatory bodies, investment sector, entrepreneurship, intellectual property law, philanthropic organizations, and advocacy groups Develops in-depth, original concepts, which have important implications in the understanding of, and search for, potential solutions to the world ́s health care crisis

Collaborative Computational Technologies for Biomedical Research

Author : Sean Ekins,Maggie A. Z. Hupcey,Antony J. Williams
Publisher : John Wiley & Sons
Page : 462 pages
File Size : 50,9 Mb
Release : 2011-08-04
Category : Science
ISBN : 9781118026021

Get Book

Collaborative Computational Technologies for Biomedical Research by Sean Ekins,Maggie A. Z. Hupcey,Antony J. Williams Pdf

Methods, Processes, and Tools for Collaboration "The time has come to fundamentally rethink how we handle the building of knowledge in biomedical sciences today. This book describes how the computational sciences have transformed into being a key knowledge broker, able to integrate and operate across divergent data types." Bryn Williams-Jones, Associate Research Fellow, Pfizer The pharmaceutical industry utilizes an extended network of partner organizations in order to discover and develop new drugs, however there is currently little guidance for managing information and resources across collaborations. Featuring contributions from the leading experts in a range of industries, Collaborative Computational Technologies for Biomedical Research provides information that will help organizations make critical decisions about managing partnerships, including: Serving as a user manual for collaborations Tackling real problems from both human collaborative and data and informatics perspectives Providing case histories of biomedical collaborations and technology-specific chapters that balance technological depth with accessibility for the non-specialist reader A must-read for anyone working in the pharmaceuticals industry or academia, this book marks a major step towards widespread collaboration facilitated by computational technologies.

Orphans and Incentives

Author : Institute of Medicine,Forum on Emerging Infections
Publisher : National Academies Press
Page : 112 pages
File Size : 49,6 Mb
Release : 1997-10-30
Category : Medical
ISBN : 9780309174411

Get Book

Orphans and Incentives by Institute of Medicine,Forum on Emerging Infections Pdf

Infectious diseases remain a leading cause of prolonged illness, premature mortality, and soaring health costs. In the United States in 1995, infectious diseases were the third leading cause of death, right behind heart disease and cancer. Mortality is mounting over time, owing to HIV/AIDS, pneumonia, and septicemia, with drug resistance playing an ever-increasing role in each of these disease categories. This book, a report from a Forum on Emerging Infections workshop, focuses on product areas where returns from the market might be perceived as being too small or too complicated by other factors to compete in industrial portfolios with other demands for investment. Vaccines are quintessential examples of such products. The lessons learned fall into four areas, including what makes intersectoral collaboration a reality, the notion of a product life cycle, the implications of divergent sectoral mandates and concepts of risk, and the roles of advocacy and public education. The summary contains an examination of the Children's Vaccine Initiative and other models, an industry perspective on the emerging infections agenda, and legal and regulatory issues.

Global Supply Chains in the Pharmaceutical Industry

Author : Nozari, Hamed,Szmelter, Agnieszka
Publisher : IGI Global
Page : 373 pages
File Size : 46,5 Mb
Release : 2018-11-09
Category : Business & Economics
ISBN : 9781522559221

Get Book

Global Supply Chains in the Pharmaceutical Industry by Nozari, Hamed,Szmelter, Agnieszka Pdf

In a rapidly growing global economy, where there is a constant emergence of new business models and dynamic changes to the business ecosystem, there is a need for the integration of traditional, new, and hybrid concepts in the complex structure of supply chain management. Within the fast-paced pharmaceutical industry, product strategy, life cycles, and distribution must maintain the highest level of agility. Therefore, organizations need strong supply chain capabilities to profitably compete in the marketplace. Global Supply Chains in the Pharmaceutical Industry provides innovative insights into the efforts needed to build and maintain a strong supply chain network in order to achieve efficient fulfillment of demand, drive outstanding customer value, enhance organizational responsiveness, and build network resiliency. This publication is designed for supply chain managers, policymakers, researchers, academicians, and students, and covers topics centered on economic cycles, sustainable development, and new forces in the global economy.

Value Creation in the Pharmaceutical Industry

Author : Alexander Schuhmacher,Markus Hinder,Oliver Gassmann
Publisher : John Wiley & Sons
Page : 508 pages
File Size : 49,8 Mb
Release : 2016-01-19
Category : Science
ISBN : 9783527693436

Get Book

Value Creation in the Pharmaceutical Industry by Alexander Schuhmacher,Markus Hinder,Oliver Gassmann Pdf

This practical guide for advanced students and decision-makers in the pharma and biotech industry presents key success factors in R&D along with value creators in pharmaceutical innovation. A team of editors and authors with extensive experience in academia and industry and at some of the most prestigious business schools in Europe discusses in detail the innovation process in pharma as well as common and new research and innovation strategies. In doing so, they cover collaboration and partnerships, open innovation, biopharmaceuticals, translational medicine, good manufacturing practice, regulatory affairs, and portfolio management. Each chapter covers controversial aspects of recent developments in the pharmaceutical industry, with the aim of stimulating productive debates on the most effective and efficient innovation processes. A must-have for young professionals and MBA students preparing to enter R&D in pharma or biotech as well as for students on a combined BA/biomedical and natural sciences program.

Knowledge Management in the Pharmaceutical Industry

Author : Elisabeth Goodman,John Riddell
Publisher : Routledge
Page : 204 pages
File Size : 50,7 Mb
Release : 2016-04-22
Category : Business & Economics
ISBN : 9781317108795

Get Book

Knowledge Management in the Pharmaceutical Industry by Elisabeth Goodman,John Riddell Pdf

The Pharmaceutical Industry has been undergoing a major transformation since the heady days of 'big pharma' in the 1970s and 80s. Patent expiry, the rise of generics, and the decline of the blockbuster drug have all changed the landscape over the last 10-15 years. It's an environment where products can take 10 years or more to come to market, billions are spent on research and development, jobs are being shed in the western pharma homelands and regulators and the public are more demanding than ever. So what part is Knowledge Management playing and going to play in this vital international industry? Knowledge Management (KM) has many facets from providing comprehensive knowledge bases for workers, through the sharing of advice and problem solving, to providing an environment for innovation and change. This book, focusing on research and development, and manufacturing-based companies, explores how a range of techniques and approaches have been applied in the unique environment of the Pharmaceutical Industry, and examine how it can help the industry in the 21st century. Whilst the book is centered on the Pharmaceutical Industry, its objective will be to discuss and demonstrate how Knowledge Management can be applied in a variety of environments, and with a range of cultural issues. KM practitioners, and potential practitioners, both within and outside the Pharmaceutical Industry, will be able to gain valuable guidance and advice from both the examples of good practice and the lessons learned by the authors and contributors.

Changing Innovation in the Pharmaceutical Industry

Author : Andre Jungmittag,Guido Reger,Thomas Reiss
Publisher : Springer Science & Business Media
Page : 216 pages
File Size : 40,8 Mb
Release : 2013-04-17
Category : Science
ISBN : 9783662041529

Get Book

Changing Innovation in the Pharmaceutical Industry by Andre Jungmittag,Guido Reger,Thomas Reiss Pdf

The internationalization of research and technology is one key component of the globalization of trade and business, with potentially major impacts on patterns of economic development and public policies worldwide. Although certain aspects of this internationalization trend are well documented, and some effects can be quantified, the overall processes are extremely complex and the outcomes are highly uncertain. The existence of the phenomenon is generally accepted, but its importance and the trends are currently the topic of a lively debate. This study on "New Ways in Drug Development in Pharmaceuticals" is part of a three year project which aims at investigating how new concepts of industrial knowledge creation are implemented in the different environ ments of the innovation systems of the United States and Germany. The main focus of the overall project is a series of case studies of innovation practice in different national and sectoral contexts. The following sectors and technological fields are investigated: pharmaceuticals and new ways in drug development by the Fraunhofer Institute for Systems and Innovation Research (ISI), advanced materials by the University Hohenheim, Insti tute of International Management and Innovation (Alexander Gerybadze), financial services and home banking by the Massachusetts Institute of Tech nology (MIT), Center for Industrial Performance (Richard Lester) and the Sloan School of Management (Edward Roberts). Financially the project was supported by the German-American Academic Council, the German Federal Minstry of Education, Science Research and Technology and the Fraunhofer Society.

Improving and Accelerating Therapeutic Development for Nervous System Disorders

Author : Institute of Medicine,Board on Health Sciences Policy,Forum on Neuroscience and Nervous System Disorders
Publisher : National Academies Press
Page : 118 pages
File Size : 45,6 Mb
Release : 2014-02-06
Category : Medical
ISBN : 9780309292498

Get Book

Improving and Accelerating Therapeutic Development for Nervous System Disorders by Institute of Medicine,Board on Health Sciences Policy,Forum on Neuroscience and Nervous System Disorders Pdf

Improving and Accelerating Therapeutic Development for Nervous System Disorders is the summary of a workshop convened by the IOM Forum on Neuroscience and Nervous System Disorders to examine opportunities to accelerate early phases of drug development for nervous system drug discovery. Workshop participants discussed challenges in neuroscience research for enabling faster entry of potential treatments into first-in-human trials, explored how new and emerging tools and technologies may improve the efficiency of research, and considered mechanisms to facilitate a more effective and efficient development pipeline. There are several challenges to the current drug development pipeline for nervous system disorders. The fundamental etiology and pathophysiology of many nervous system disorders are unknown and the brain is inaccessible to study, making it difficult to develop accurate models. Patient heterogeneity is high, disease pathology can occur years to decades before becoming clinically apparent, and diagnostic and treatment biomarkers are lacking. In addition, the lack of validated targets, limitations related to the predictive validity of animal models - the extent to which the model predicts clinical efficacy - and regulatory barriers can also impede translation and drug development for nervous system disorders. Improving and Accelerating Therapeutic Development for Nervous System Disorders identifies avenues for moving directly from cellular models to human trials, minimizing the need for animal models to test efficacy, and discusses the potential benefits and risks of such an approach. This report is a timely discussion of opportunities to improve early drug development with a focus toward preclinical trials.

Conflict of Interest in Medical Research, Education, and Practice

Author : Institute of Medicine,Board on Health Sciences Policy,Committee on Conflict of Interest in Medical Research, Education, and Practice
Publisher : National Academies Press
Page : 436 pages
File Size : 55,6 Mb
Release : 2009-09-16
Category : Medical
ISBN : 9780309145442

Get Book

Conflict of Interest in Medical Research, Education, and Practice by Institute of Medicine,Board on Health Sciences Policy,Committee on Conflict of Interest in Medical Research, Education, and Practice Pdf

Collaborations of physicians and researchers with industry can provide valuable benefits to society, particularly in the translation of basic scientific discoveries to new therapies and products. Recent reports and news stories have, however, documented disturbing examples of relationships and practices that put at risk the integrity of medical research, the objectivity of professional education, the quality of patient care, the soundness of clinical practice guidelines, and the public's trust in medicine. Conflict of Interest in Medical Research, Education, and Practice provides a comprehensive look at conflict of interest in medicine. It offers principles to inform the design of policies to identify, limit, and manage conflicts of interest without damaging constructive collaboration with industry. It calls for both short-term actions and long-term commitments by institutions and individuals, including leaders of academic medical centers, professional societies, patient advocacy groups, government agencies, and drug, device, and pharmaceutical companies. Failure of the medical community to take convincing action on conflicts of interest invites additional legislative or regulatory measures that may be overly broad or unduly burdensome. Conflict of Interest in Medical Research, Education, and Practice makes several recommendations for strengthening conflict of interest policies and curbing relationships that create risks with little benefit. The book will serve as an invaluable resource for individuals and organizations committed to high ethical standards in all realms of medicine.

Establishing Precompetitive Collaborations to Stimulate Genomics-Driven Product Development

Author : Institute of Medicine,Board on Health Sciences Policy,Roundtable on Translating Genomic-Based Research for Health
Publisher : National Academies Press
Page : 90 pages
File Size : 42,7 Mb
Release : 2011-02-17
Category : Medical
ISBN : 9780309209618

Get Book

Establishing Precompetitive Collaborations to Stimulate Genomics-Driven Product Development by Institute of Medicine,Board on Health Sciences Policy,Roundtable on Translating Genomic-Based Research for Health Pdf

Despite the many basic research discoveries in genetics, relatively few gene-based treatments, drugs, or preventative measures have been developed. One way to bridge this gap may be for industry, academia, and government to develop partnerships that share resources while distributing risk. However, intellectual property protections and other barriers can inhibit collaborative efforts. The Institute of Medicine held a workshop on July 22, 2010, to explore these issues and develop solutions.

Leading Pharmaceutical Innovation

Author : Oliver Gassmann,Gerrit Reepmeyer,Maximilian von Zedtwitz
Publisher : Springer Science & Business Media
Page : 186 pages
File Size : 54,8 Mb
Release : 2008-02-19
Category : Business & Economics
ISBN : 9783540776369

Get Book

Leading Pharmaceutical Innovation by Oliver Gassmann,Gerrit Reepmeyer,Maximilian von Zedtwitz Pdf

Pharmaceutical giants have been doubling their investments in drug development, only to see new drug approvals to remain constant for the past decade. This book investigates and highlights a set of proactive strategies, aimed at generating sustainable competitive advantage for its protagonists based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of internationalisation, such as outside-in innovation in the early phases of R&D.

Digital Strategies in the Pharmaceutical Industry

Author : L. Lerer,M. Piper
Publisher : Springer
Page : 256 pages
File Size : 42,6 Mb
Release : 2003-01-24
Category : Business & Economics
ISBN : 9780230598799

Get Book

Digital Strategies in the Pharmaceutical Industry by L. Lerer,M. Piper Pdf

This book is a comprehensive review of the current state of digital innovation, Internet activity and e-business in the life sciences arena and a practical guide for managers planning, developing and implementing e-strategies in the pharmaceutical industry. The authors provide numerous examples of innovative, best practice and lay the strategic foundation for using e-business across the pharmaceutical value chain from drug discovery to physician promotion to direct-to-consumer marketing.